Philip Ehrlich, MD
Ophthalmology · Baton Rouge, LANPI 1497706550
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Alcon at 50.6% of the total. 2025 is the largest year on record at $1,632, 2.6 times the $632 reported in 2019.
Across 167 payments — averaging $37.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Glaukos Corporation$950
- AbbVie$516
- Nova Eye, Inc.$307
- Aerie Pharmaceuticals, Inc.$220
- Bausch & Lomb Americas Inc.$193
- plus $873 from 14 others
What the payments were for
- Food & beverage$5,89095%
- Entertainment$3075%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 80 | $3,138 |
| Glaukos Corporation | 11 | $950 |
| AbbVie(2 entities) | 26 | $516 |
| Nova Eye, Inc. | 1 | $307 |
| Aerie Pharmaceuticals, Inc. | 14 | $220 |
| Bausch & Lomb Americas Inc. | 2 | $193 |
| Kala Pharmaceuticals, Inc. | 7 | $169 |
| Rxsight Inc | 1 | $121 |
| Tarsus Pharmaceuticals, Inc. | 1 | $98 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $96 |
| Sun Pharmaceutical Industries Inc. | 5 | $91 |
| Dompe US, Inc. | 3 | $83 |
| Amgen | 1 | $41 |
| Iridex Corporation | 1 | $37 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
| Biotissue Holdings Inc. | 1 | $28 |
| Ivantis, Inc | 2 | $27 |
| Shire North American Group Inc | 1 | $21 |
| Harrow Eye, LLC | 1 | $16 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$791
- Hydrus Microstent$378
- iDoseTR$295
- iStent Trabecular Micro-Bypass System Model iS3$173
- ReSTOR$139
- iStent inject W$137
- AcrySof IQ PanOptix$133
- LenSx$132
- TRYPTYR$122
- RXSIGHT CONTACT LENS$121
- RXSIGHT INJECTOR CARTRIDGE$121
- RXSIGHT INJECTOR HANDPIECE$121
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$121
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$121
How this compares
$6,197 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 356 | $196,684 |
| LumiganBimatoprost | 275 | $139,906 |
| CombiganBrimonidine Tartrate/Timolol | 261 | $103,597 |
| RestasisCyclosporine | 70 | $70,068 |
| RocklatanNetarsudil Mesylat/Latanoprost | 129 | $66,382 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 107 | $32,815 |
| Prednisolone Acetate | 619 | $32,140 |
| Travoprost | 157 | $31,103 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 147 | $27,684 |
| Alphagan PBrimonidine Tartrate | 55 | $27,620 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,201 | $23,237 |
| Latanoprost | 2,168 | $22,540 |
| Brimonidine Tartrate | 964 | $16,995 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 59 | $9,660 |
| Brinzolamide | 40 | $8,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $516 | $341,191661 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $220 | $263,066485 claims |
| AlconSimbrinza | $3,138 | $32,815107 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $96 | $2,93416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Baton Rouge
- Blake WilliamsonBaton Rouge$443K
- Charles WilliamsonBaton Rouge$16K
- David FargasonBaton Rouge$6K
- Daniel NelsonBaton Rouge$6K
- Michael MorganBaton Rouge$6K
- Thomas StuckeyBaton Rouge$6K
- George FivgasBaton Rouge$6K
- Devin TranBaton Rouge$5K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.